Search Results - "Wallenstein, Gene V"

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis by Fleischmann, Roy, Kremer, Joel, Cush, John, Schulze-Koops, Hendrik, Connell, Carol A, Bradley, John D, Gruben, David, Wallenstein, Gene V, Zwillich, Samuel H, Kanik, Keith S

“…In a placebo-controlled trial, monotherapy with tofacitinib, an oral Janus kinase inhibitor, reduced the symptoms and signs of rheumatoid arthritis. Adverse…”
Get full text

Tofacitinib versus Methotrexate in Rheumatoid Arthritis by Lee, Eun Bong, Fleischmann, Roy, Hall, Stephen, Wilkinson, Bethanie, Bradley, John D, Gruben, David, Koncz, Tamas, Krishnaswami, Sriram, Wallenstein, Gene V, Zang, Chuanbo, Zwillich, Samuel H, van Vollenhoven, Ronald F

“…In patients with rheumatoid arthritis, tofacitinib was associated with greater reductions in signs and symptoms than methotrexate. Herpes zoster infections and…”
Get full text

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis by van Vollenhoven, Ronald F, Fleischmann, Roy, Cohen, Stanley, Lee, Eun Bong, García Meijide, Juan A, Wagner, Sylke, Forejtova, Sarka, Zwillich, Samuel H, Gruben, David, Koncz, Tamas, Wallenstein, Gene V, Krishnaswami, Sriram, Bradley, John D, Wilkinson, Bethanie

“…In this trial of patients with rheumatoid arthritis who were on stable doses of methotrexate, tofacitinib, a novel oral Janus kinase inhibitor, was more…”
Get full text

Interpreting score differences in the Insomnia Severity Index: using health-related outcomes to define the minimally important difference by Yang, Min, Morin, Charles M., Schaefer, Kendyl, Wallenstein, Gene V.

“…Abstract Objective: To estimate the minimally important difference (MID) for the Insomnia Severity Index (ISI) by examining the association of score…”
Get full text

Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis by Vieira, Maria-Cecilia, PhD, Zwillich, Samuel H., MD, Jansen, Jeroen P., PhD, Smiechowski, Brielan, MSc, Spurden, Dean, PhD, Wallenstein, Gene V., MD

“…Abstract Purpose Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This analysis compared the efficacy and safety…”
Get full text

Interpreting score differences in the SF-36 Vitality scale: using clinical conditions and functional outcomes to define the minimally important difference by Bjorner, Jakob B., Wallenstein, Gene V., Martin, Marie C., Lin, Peggy, Blaisdell-Gross, Bonnie, Tak Piech, Catherine, Mody, Samir H.

“…ABSTRACT Objective: To propose the minimally important difference (MID) for the SF-36 Vitality (VT) scale by evaluating the association of score differences…”
Get full text

The hippocampus as an associator of discontiguous events by Wallenstein, Gene V., Hasselmo, Michael E., Eichenbaum, Howard

“…The hippocampus has long been thought to be an important cortical region for associative learning and memory. After several decades of experimental and…”
Get full text

GABAergic Modulation of Hippocampal Population Activity: Sequence Learning, Place Field Development, and the Phase Precession Effect by Wallenstein, Gene V, Hasselmo, Michael E

“…Gene V. Wallenstein and Michael E. Hasselmo Department of Psychology and Program in Neuroscience, Harvard University, Cambridge, Massachusetts 02138…”
Get full text

Tofacitinib in Combination With Conventional Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Randomized Controlled Trial by Strand, Vibeke, Kremer, Joel M., Gruben, David, Krishnaswami, Sriram, Zwillich, Samuel H., Wallenstein, Gene V.

“…Objective Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared patient‐reported outcomes (PROs) in…”
Get full text

A psychometric comparison of three patient-based measures of asthma control by Wallenstein, Gene V., Carranza-Rosenzweig, Jacqueline, Kosinski, Mark, Blaisdell-Gross, Bonnie, Gajria, Kavita, Jhingran, Priti

“…ABSTRACT Objective: Asthma is a multidimensional disease, characterized by changes in pulmonary function, transient and chronic symptoms, and effects on…”
Get full text

Intrahippocampal Scopolamine Impairs Both Acquisition and Consolidation of Contextual Fear Conditioning by Wallenstein, Gene V., Vago, David R.

“…Lesions of the dorsal hippocampus have been shown to disrupt both the acquisition and the consolidation of memories associated with contextual fear (fear of…”
Get full text

Modelling the cost-effectiveness of tofacitinib for the treatment of rheumatoid arthritis in the United States by Claxton, Lindsay, Taylor, Matthew, Gerber, Robert A., Gruben, David, Moynagh, Dermot, Singh, Amitabh, Wallenstein, Gene V.

“…Background and objectives: Rheumatoid arthritis (RA) is a chronic, debilitating disease affecting an estimated 1.5 million patients in the US. The condition is…”
Get full text

Tofacitinib With Methotrexate in Third‐Line Treatment of Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Trial by Strand, Vibeke, Burmester, Gerd R., Zerbini, Cristiano A. F., Mebus, Charles A., Zwillich, Samuel H., Gruben, David, Wallenstein, Gene V.

“…Objective To assess patient‐reported outcomes (PROs) for tofacitinib, an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA), in a 6‐month, phase…”
Get full text

Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors by Rendas-Baum, Regina, Wallenstein, Gene V, Koncz, Tamas, Kosinski, Mark, Yang, Min, Bradley, John, Zwillich, Samuel H

“…The long-term treatment of rheumatoid arthritis (RA) most often involves a sequence of different therapies. The response to therapy, disease progression and…”
Get full text

Estimated medical expenditure and risk of job loss among rheumatoid arthritis patients undergoing tofacitinib treatment: post hoc analyses of two randomized clinical trials by Rendas-Baum, Regina, Kosinski, Mark, Singh, Amitabh, Mebus, Charles A, Wilkinson, Bethany E, Wallenstein, Gene V

“…RA causes high disability levels and reduces health-related quality of life, triggering increased costs and risk of unemployment. Tofacitinib is an oral Janus…”
Get full text

Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial by Strand, Vibeke, Mysler, Eduardo, Moots, Robert J, Wallenstein, Gene V, DeMasi, Ryan, Gruben, David, Soma, Koshika, Iikuni, Noriko, Smolen, Josef S, Fleischmann, Roy

“…ObjectiveTo provide the first direct comparison of patient-reported outcomes (PROs) following treatment with tofacitinib monotherapy versus tofacitinib or…”
Get full text

Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials by Wallenstein, Gene V, Kanik, Keith S, Wilkinson, Bethanie, Cohen, Stanley, Cutolo, Maurizio, Fleischmann, Roy, Genovese, Mark C, Gomez Reino, Juan, Gruben, David, Kremer, Joel, Krishnaswami, Sriram, Lee, Eun Bong, Pascual-Ramos, Virginia, Strand, Vibeke, Zwillich, Samuel H

“…Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we investigated the effects of tofacitinib on…”
Get full text

A novel approach to estimate the minimally important difference for the fatigue impact scale in multiple sclerosis patients by Rendas-Baum, Regina, Yang, Min, Cattelin, Francoise, Wallenstein, Gene V., Fisk, John D.

“…Purpose The Fatigue Impact Scale (FIS) has been used extensively to assess the impact of fatigue on health-related quality of life (HRQOL) in multiple…”
Get full text

Measuring the effect of therapy in rheumatoid arthritis clinical trials from the patient's perspective by Rendas-Baum, Regina, Bayliss, Martha, Kosinski, Mark, Raju, Aditya, Zwillich, Samuel H., Wallenstein, Gene V., Koncz, Tamas

“…Abstract Objective: Health measurements used to evaluate the effectiveness of rheumatoid arthritis (RA) therapies often fail to reflect patients' priorities,…”
Get full text

Meta-analysis of long-term joint structural deterioration in minimally treated patients with rheumatoid arthritis by Jansen, Jeroen P, Vieira, Maria-Cecilia, Bradley, John D, Cappelleri, Joseph C, Zwillich, Samuel H, Wallenstein, Gene V

“…Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation and joint structural deterioration. Driven by recent expectations that…”
Get full text